Sanofi (SNY)
Preborsa:
| Chiusura precedente | 56,29 |
| Aperto | 55,62 |
| Denaro | 0,00 x 800 |
| Lettera | 0,00 x 1100 |
| Min-Max giorno | 55,57 - 55,95 |
| Intervallo di 52 settimane | 46,93 - 58,10 |
| Volume | |
| Media Volume | 2.245.859 |
| Capitalizzazione | 139,475B |
| Beta (5 anni mensile) | 0,36 |
| Rapporto PE (ttm) | 19,72 |
| EPS (ttm) | 2,83 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | 1,80 (3,19%) |
| Data ex dividendo | 26 mag 2022 |
| Stima target 1A | 70,75 |
- GlobeNewswire
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA’s Priority Review action date Dupixent 300 mg weekly significantly improved signs and symptoms of eosinophilic esophagitis compared to placebo in a Phase 3 trial, underscoring the role of type 2 inflammation in this c
- GlobeNewswire
Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy Latest results of the Phase 3 IKEMA trial demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in patients who relapsed after a prior therapy, including lenalidomideThe median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilz
- GlobeNewswire
Press Release: New nirsevimab data analyses reinforce efficacy against RSV
New nirsevimab data analyses reinforce efficacy against RSV A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV)1Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single doseTwo analyses are being presented at the European Society for Paediatric Infecti
